Biliverdin protects against cisplatin-induced apoptosis of renal tubular epithelial cells

Abstract

Biliverdin (BV) has long been thought to be a cytotoxic metabolic waste product. It has also been demonstrated to have important cytoprotective functions during oxidative stress. The present study aimed to examine the cytoprotective effect of BV on NRK-52E cells, a proximal tubular cell line derived from rat kidney. Cells were treated with 50 µmol/L cisplatin for 24 h (cisplatin group) or pre-treated with BV for 30 min, then with 50 µmol/L cisplatin for 24 h (cisplatin+BV group). Those given no treatment served as a control. Cell apoptosis was evaluated by flow cytometry and cell viability by Cell Counting Kit-8 (CCK-8). The protein expressions of cleaved caspase3, Bax and Bcl-2 were assessed by Western blotting. Reactive oxygen species (ROS) levels were measured using carboxydichlorodihydrofluorescein diacetate (H2DCF). The results showed that cisplatin induced the apoptosis of NRK-52E cells, decreased cell viability, and increased the formation of ROS by upregulating the expression of cleaved caspase3 and Bax and decreasing Bcl-2 protein expression. These effects could be significantly reversed by pretreatment with BV. It was concluded that BV can protect against cisplatin-induced cell apoptosis through the anti-oxidative effects.

Keywords

biliverdin / cisplatin / apoptosis / reactive oxygen species

References

[1] BagshawSM. Short-and long-term survival after acute kidney injury. Nephrol Dial Transplant, 2008, 23(7): 2126-2128 PMID: 18587158

[2] ChertowGM, BurdickE, HonourM, et al. . Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol, 2005, 16(11): 3365-3370 PMID: 16177006

[3] TogelFE, WestenfelderC. Kidney protection and regeneration following acute injury: progress through stem cell therapy. Am J Kidney Dis, 2012, 60(6): 1012-1022 PMID: 23036928

[4] WaikarSS, LiuKD, ChertowGM. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol, 2008, 3(3): 844-861 PMID: 18337550

[5] FukasawaH, FuruyaR, YasudaH, et al. . Anti-cancer agent-induced nephrotoxicity. Anticancer Agents Med Chem, 2014, 14(7): 921-927 PMID: 24476314

[6] PeresLA, da CunhaADJr.. Acute nephrotoxicity of cisplatin: molecular mechanisms. J Bras Nefrol, 2013, 35(4): 332-340 PMID: 24402113

[7] CamanoS, LazaroA, Moreno-GordalizaE, et al. . Cilastatin attenuates cisplatin-induced proximal tubular cell damage. J Pharmacol Exp Ther, 2010, 334(2): 419-429 PMID: 20435919

[8] dos SantosNA, Carvalho RodriguesMA, MartinsNM, et al. . Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol, 2012, 86(8): 1233-1250 PMID: 22382776

[9] PablaN, DongZ. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int, 2008, 73(9): 994-1007 PMID: 18272962

[10] Sanchez-GonzalezPD, Lopez-HernandezFJ, Lopez-NovoaJM, et al. . An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit Rev Toxicol, 2011, 41(10): 803-821 PMID: 21838551

[11] StockerR, YamamotoY, McDonaghAF, et al. . Bilirubin is an antioxidant of possible physiological importance. Science, 1987, 235(4792): 1043-1046 PMID: 3029864

[12] BarananoDE, RaoM, FerrisCD, et al. . Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA, 2002, 99(25): 16093-16098 PMCID: 138570 PMID: 12456881

[13] Lerner-MarmaroshN, MiralemT, GibbsPE, et al. . Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling. Proc Natl Acad Sci USA, 2008, 105(19): 6870-6875 PMCID: 2383961 PMID: 18463290

[14] MainesMD. New insights into biliverdin reductase functions: linking heme metabolism to cell signaling. Physiology, 2005, 20(6): 382-389 PMID: 16287987

[15] KapitulnikJ, MainesMD. Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol Sci, 2009, 30(3): 129-137 PMID: 19217170

[16] Lerner-MarmaroshN, ShenJ, TornoMD. Human biliverdin reductase: a member of the insulin receptor substrate family with serine/threonine/tyrosine kinase activity. Proc Natl Acad Sci USA, 2005, 102(20): 7109-7114 PMCID: 1088173 PMID: 15870194

[17] SedlakTW, SnyderSH. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics, 2004, 113(6): 1776-1782 PMID: 15173506

[18] BulmerAC, BlanchfieldJT, CoombesJS, et al. . In vitro permeability and metabolic stability of bile pigments and the effects of hydrophilic and lipophilic modification of biliverdin. Bioorg Med Chem, 2008, 16(7): 3616-3625 PMID: 18304823

[19] Sheikh-HamadD, CaciniW, BuckleyAR, et al. . Cellular and molecular studies on cisplatin-induced apoptotic cell death in rat kidney. Arch Toxicol, 2004, 78(3): 147-155 PMID: 14551673

[20] BoulikasT, VougioukaM. Cisplatin and platinum drugs at the molecular level. Oncol Rep, 2003, 10(6): 1663-1682 PMID: 14534679

[21] SugimotoR, TanakaY, NodaK, et al. . Preservation solution supplemented with biliverdin prevents lung cold ischaemia/reperfusion injury. Eur J Cardiothorac Surg, 2012, 42(6): 1035-1041 PMCID: 4334840 PMID: 22648925

[22] IkedaN, InoguchiT, SonodaN, et al. . Biliverdin protects against the deterioration of glucose tolerance in db/db mice. Diabetologia, 2011, 54(8): 2183-2191 PMID: 21614569

[23] BaiB, LiuY, YouY, et al. . Intraperitoneally administered biliverdin protects against UVB-induced skin photodamage in hairless mice. J Photochem Photobiol B, 2015, 144: 35-41 PMID: 25689514

[24] YamashitaT, DeguchiK, SeharaY, et al. . Therapeutic strategy for ischemic stroke. Neurochem Res, 2009, 34(4): 707-710 PMID: 18770029

[25] BishtK, TampeJ, ShingC, et al. . Endogenous tetrapyrroles influence leukocyte responses to lipopolysaccharide in human blood: pre-clinical evidence demonstrating the anti-inflammatory potential of biliverdin. J Clin Cell Immunol, 2014, 5(218): 1000218 PMCID: 4145741 PMID: 25177524